Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 40.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 73,135 shares of the company’s stock after selling 50,195 shares during the period. The Manufacturers Life Insurance Company owned about 0.06% of Apellis Pharmaceuticals worth $2,805,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Future Financial Wealth Managment LLC purchased a new stake in Apellis Pharmaceuticals during the 1st quarter worth about $29,000. BI Asset Management Fondsmaeglerselskab A S purchased a new stake in shares of Apellis Pharmaceuticals during the 1st quarter worth approximately $89,000. nVerses Capital LLC boosted its holdings in shares of Apellis Pharmaceuticals by 300.0% in the 2nd quarter. nVerses Capital LLC now owns 2,800 shares of the company’s stock valued at $107,000 after buying an additional 2,100 shares in the last quarter. Russell Investments Group Ltd. raised its stake in Apellis Pharmaceuticals by 1,300.8% during the 1st quarter. Russell Investments Group Ltd. now owns 3,586 shares of the company’s stock worth $211,000 after acquiring an additional 3,330 shares in the last quarter. Finally, Sierra Summit Advisors LLC purchased a new stake in Apellis Pharmaceuticals in the fourth quarter valued at $222,000. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Insiders Place Their Bets

In other news, Director A. Sinclair Dunlop sold 37,000 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $36.23, for a total transaction of $1,340,510.00. Following the completion of the sale, the director now directly owns 100,000 shares in the company, valued at approximately $3,623,000. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have recently weighed in on APLS shares. The Goldman Sachs Group boosted their target price on Apellis Pharmaceuticals from $66.00 to $74.00 and gave the company a “buy” rating in a report on Friday, August 9th. Needham & Company LLC restated a “buy” rating and set a $85.00 target price on shares of Apellis Pharmaceuticals in a research report on Friday, September 20th. Wedbush upped their price target on shares of Apellis Pharmaceuticals from $38.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, August 9th. Wells Fargo & Company lowered their price objective on shares of Apellis Pharmaceuticals from $47.00 to $43.00 and set an “equal weight” rating on the stock in a research report on Tuesday, September 24th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $80.00 target price on shares of Apellis Pharmaceuticals in a report on Wednesday, July 31st. Four equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $70.20.

Apellis Pharmaceuticals Stock Down 0.2 %

APLS opened at $27.40 on Wednesday. The business has a 50 day simple moving average of $35.55 and a 200-day simple moving average of $41.09. Apellis Pharmaceuticals, Inc. has a 12 month low of $26.69 and a 12 month high of $73.80. The stock has a market capitalization of $3.33 billion, a P/E ratio of -7.92 and a beta of 0.87. The company has a debt-to-equity ratio of 1.73, a current ratio of 5.08 and a quick ratio of 4.18.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Thursday, August 1st. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.03. The company had revenue of $199.70 million for the quarter, compared to analyst estimates of $190.89 million. Apellis Pharmaceuticals had a negative net margin of 52.99% and a negative return on equity of 138.32%. The business’s revenue was up 110.2% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.02) EPS. On average, equities analysts anticipate that Apellis Pharmaceuticals, Inc. will post -1.34 earnings per share for the current fiscal year.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).